Additional file 4 of HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN
Year: 2025
Type: article
Abstract: Supplementary Figure 4
Source: Figshare
Authors: Schmidt, Gilda, Gluz, Oleg, Christgen, Matthias, Reinisch, Mattea, Kümmel, Sherko, Nitz, Ulrike, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Mahlberg, Rolf, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Stefek, Andrea, Wuerstlein, Rachel, Graeser, Monika, Jóźwiak, Katarzyna, Burmeister, Sandy, zu Eulenburg, Christine, Lauseker, Michael, Kolberg-Liedtke, Cornelia, Prat, Aleix, Schmid, Peter, Baehner, Rick, Kreipe, Hans Heinrich, Solomayer, Erich-Franz, Harbeck, Nadia
Institutions: Saarland University, Evangelisches Krankenhaus Bethesda Mönchengladbach, Women‘s Healthcare Group, Medizinische Hochschule Hannover, University Medical Centre Mannheim, Charité - Universitätsmedizin Berlin, Elisabeth-Krankenhaus Essen, Klinikum Mutterhaus der Borromäerinnen, Universitätsklinikum Erlangen, Ludwig-Maximilians-Universität München, University Medical Center Hamburg-Eppendorf, Medizinische Hochschule Brandenburg Theodor Fontane, LMU Klinikum, Essen University Hospital, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Queen Mary University of London, Exact Sciences (United States)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6902308387
FWCI:
Cites:
Cited by:
Related to: